---
title: "Inovio Pharmaceuticals, Inc. (INO.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/INO.US.md"
symbol: "INO.US"
name: "Inovio Pharmaceuticals, Inc."
industry: "Biotechnology"
datetime: "2026-05-19T19:14:15.205Z"
locales:
  - [en](https://longbridge.com/en/quote/INO.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/INO.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/INO.US.md)
---

# Inovio Pharmaceuticals, Inc. (INO.US)

## Company Overview

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company’s lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.inovio.com](https://www.inovio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: E
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: E (0.87)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 365 / 386 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: E

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | 11.97% |  |
| P/B Ratio | 16.40 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 99542186.32 |  |
| Revenue | 0.00 |  |

#### Multi Score Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -296.36% | E |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |
| Revenue YoY | -100.00% | E |
| Net Profit YoY | 11.97% | C |
| Total Assets YoY | -42.96% | E |
| Net Assets YoY | -88.16% | E |
| Cash Flow Margin | 98.13% | C |
| OCF YoY | -100.00% | E |
| Turnover | 0.00 | E |
| Gearing Ratio | 87.81% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Inovio Pharmaceuticals, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "11.97%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "16.40",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "99542186.32",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "0.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-296.36%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "11.97%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "-42.96%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-88.16%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "98.13%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "87.81%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.17 | 191/386 | - | - | - |
| PB | 16.40 | 410/386 | 4.60 | 3.86 | 1.45 |
| PS (TTM) | 1673.22 | - | 836.47 | 655.77 | 275.93 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-14T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 40% |
| Overweight | 1 | 20% |
| Hold | 2 | 40% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 1.21 |
| Highest Target | 13.00 |
| Lowest Target | 1.80 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/INO.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/INO.US/norm.md)
- [Related News](https://longbridge.com/en/quote/INO.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/INO.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**